After it drops 13.5% in a day, is it time I bought this S&P 500 growth stock?

The Eli Lilly (NYSE:LLY) share price fell by double digits in the S&P 500 today, leaving this Fool debating whether he should reinvest.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The flag of the United States of America flying in front of the Capitol building

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Eli Lilly (NYSE: LLY) has been one of the standout stocks in the S&P 500 in recent years. It’s up 597% in five years and a whopping 1,090% over the past decade. That’s mightily impressive for a mature pharma firm.

In the past couple of years, the company’s upwards trajectory was given a turbo-boost by its blockbuster GLP-1 drugs Mounjaro and Zepbound. The latter was approved late last year specifically for weight loss, which is a market that is expected to drive massive sales long into the future.

Today (30 October), however, the Eli Lilly share price slumped 13% after the company’s third-quarter results disappointed Wall Street. This rare stumble leaves me wondering if I should pick up some shares while they’re down.

Should you invest £1,000 in Unilever right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Unilever made the list?

See the 6 stocks

Created with Highcharts 11.4.3Eli Lilly PriceZoom1M3M6MYTD1Y5Y10YALL30 Oct 201930 Oct 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

What happened

Heading into the quarter, analysts expected $12.1bn in revenue and adjusted earnings per share (EPS) of $1.47. But the company reported revenue of $11.4bn and adjusted EPS of $1.18. So there was an earnings miss and the firm lowered its full-year EPS guidance, to $13.02-$13.52 from $16.10-$16.60.

Still, the quarter didn’t look bad to me. Far from it. Revenue increased 20% year on year, driven by growth from Mounjaro and Zepbound. Excluding $1.42bn in Q3 2023 from the sale of rights for its olanzapine (antipsychotics) portfolio, revenue surged 42%!

Outside of weight-loss drugs, there was impressive 17% revenue growth in oncology, immunology, and neuroscience. This was a very strong quarter, despite what the share price drop might suggest.

Expanding markets

Eli Lilly’s market cap is now $748bn, which makes it one of the largest companies in the world. But if the likes of Apple, Amazon, and Microsoft have taught us anything, it’s that the already big can carry on getting bigger, as long as they keep finding new avenues of growth.

In this regard, I’m bullish on the company’s prospects. According to Morgan Stanley, the global market for blockbuster obesity drugs could increase by more than 15-fold by 2030. This is due to them potentially spreading beyond weight loss to treat a range of diseases.

For example, early research suggests that these GLP-1 drugs may have neuroprotective effects and could potentially slow the progression of Alzheimer’s disease. They also reportedly reduce alcohol intake, so could potentially treat addiction.

Of course, it’s early days to know any of this for sure. And there could be some negative long-term effects with these weight-loss drugs that we don’t know about. That’s a key risk, as is competition from market leader Novo Nordisk, the maker of Wegovy and Ozempic.

Also, due to high demand and supply shortages, there are loads of cheaper knock-offs floating about.

Should I rebuy?

I owned Eli Lilly stock a while back. However, I sold after it doubled in a year and the price-to-earnings (P/E) multiple went well above 100.

Currently though, the forward P/E ratio here is 37, falling to 24 by 2027. For a company with such a strong position in multiple massive growth markets — it also recently got an Alzheimer’s drug, donanemab, approved — I don’t think that’s outrageous.

Looking ahead, I reckon Eli Lilly looks likely to become the first $1trn drug company. I’ve put the stock back on my watchlist, with an eye to reinvesting at some point.

Should you buy Unilever now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has recommended Amazon, Apple, Microsoft, and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our best passive income stock ideas

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

With Cash ISA changes coming, could now be the time to consider buying shares?

Changes to the Cash ISA could lead to greater investment in the stock market. This could be a good thing…

Read more »

Investing Articles

These FTSE 100 dividend shares just got cheaper, thanks to President Trump!

Investors buying dividend shares can lock in bigger long-term yields when share prices take a tumble. These two just did…

Read more »

Investing Articles

At a 52-week low but Taylor Wimpey shares are forecast to rise 35% in a year and yield almost 9%!

Taylor Wimpey shares have had a rough ride but Harvey Jones says analyst forecasts are upbeat, while there is also…

Read more »

Investing Articles

As copper prices surge, Glencore shares are a steal at 270p

Andrew Mackie believes the extraordinary dislocation occurring in copper markets will be very supportive for the Glencore share price.

Read more »

Investing Articles

2 cheap shares to consider as Trump shocks markets

Dr James Fox examines several cheap shares, on paper at least, as markets experience a broad sell-off in reaction to…

Read more »

Investing Articles

10% dividend yield! Here’s a FTSE 100 share to consider in April for passive income

This FTSE 100 stock just soared past the 10% yield mark, making it a potentially lucrative option for investors targeting…

Read more »

Young black woman using a mobile phone in a transport facility
Investing Articles

3 FTSE 100 safe haven stocks to consider as trade wars bite

I'm confident in the long-term outlook for the FTSE index of stocks. But these blue chips may protect investors from…

Read more »

Investing Articles

Here’s how Trump tariffs could hand us some top passive income bargains

As tariff terror grips the stock market, it's time for passive income investors to steel our nerves and look for…

Read more »